PBF-999 / Palobiofarma, Xoma - LARVOL DELTA

Palobiofarma Secures €7 Million Investment: Paving the Way for Transformative Treatments (BNN Breaking) - "The Spain-based company, specializing in new drug discovery through adenosine receptors modulation, recently announced a €7 million investment round led by Inveready, Sodena, and the company's founders....This significant financial boost will enable Palobiofarma to complete three Phase II clinical trials for their promising products PBF-680, PBF-999...These innovative therapies target chronic obstructive pulmonary disease (COPD), Prader-Willi syndrome...conditions that currently affect millions worldwide....The funds will also support the company's mission to ink new licensing agreements for its advanced-stage assets."

Financing • Chronic Obstructive Pulmonary Disease • Prader–Willi syndrome

Study of PBF-999 in Solid Tumour Advanced Cancer (clinicaltrials.gov) - P1 | N=54 | Completed | Sponsor: Palobiofarma SL | Recruiting ➔ Completed | N=40 ➔ 54

Enrollment change • Metastases • Trial completion • Oncology • Solid Tumor

Study of PBF-999 in Solid Tumour Advanced Cancer (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Palobiofarma SL; Trial completion date: Feb 2022 ➔ Jun 2022; Trial primary completion date: Dec 2021 ➔ Apr 2022

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • MRI

Study of PBF-999 in Solid Tumour Advanced Cancer (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Palobiofarma SL; Trial completion date: Dec 2019 ➔ Feb 2022; Trial primary completion date: Oct 2019 ➔ Dec 2021

Trial completion date • Trial primary completion date • Oncology • Solid Tumor